Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2009-09-04 Regulatory Filings
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings
2009-09-04 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Arrowhead Research Corporation. It addresses specific comments about the selling security holders' share numbers and mentions an Amendment No. 1 to the registration statement. The document is short (2116 characters) and primarily serves as a correspondence or regulatory response rather than a financial report or filing itself. It does not contain financial statements or substantive financial data, nor is it a report like a 10-K or S-1 registration statement itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence with regulators that do not fit other categories.
2009-08-28 English
AMENDMENT NO. 1 TO FORM S-1
Regulatory Filings Classification · 95% confidence The document is titled 'Amendment No. 1 to Form S-1 Registration Statement' filed with the SEC. Form S-1 is a registration statement used by companies planning to go public or register securities for sale. The text includes detailed information about the company, the securities being registered, risk factors, use of proceeds, selling stockholders, and other typical content of a registration statement. It is not an earnings release, annual report, or any other financial report but a regulatory filing related to securities registration. The document is lengthy (15,000 characters) and contains substantive information typical of an S-1 amendment filing. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2009-08-28 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm responding to comments from the SEC staff regarding a Preliminary Proxy Statement on Schedule 14A filed by Arrowhead Research Corporation. The letter addresses SEC comments about disclosures related to proposals in the proxy statement, including reverse stock splits, authorized shares, option grants, and conflicts of interest. The document does not contain the proxy statement itself but is a correspondence related to the proxy filing process. It is not a report, financial statement, or announcement of voting results. Given the nature of the document as a regulatory correspondence about a proxy statement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2009-08-27 English
REVISED PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled as a "Revised Preliminary Proxy Statement" and references SEC Schedule 14A, which is the standard form for proxy statements filed with the SEC. The content includes detailed information about a Special Meeting of Stockholders, including proposals to be voted on, voting instructions, record dates, and proxy solicitation details. It discusses matters such as a reverse stock split, increasing authorized shares, and equity grants, all typical subjects of proxy statements. There is no indication that this is a full annual report, earnings release, or other financial report. The document is not a voting results announcement but rather the solicitation material for a shareholder vote. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the proxy statement itself, not just an announcement of it.
2009-08-27 English
Regulatory Filings 2009
Regulatory Filings
2009-08-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.